Related Experiment Video
Updated: May 15, 2026

The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Rational therapy for renal cell carcinoma based on its genetic targets
Jamie Messer1, Joseph Drabick, Matthew Kaag
1Department of Surgery (Division of Urology), Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA.
Abstract:
Renal cell carcinoma (RCC) is not a single entity, rather it is a term defining a group of histologically distinct tumors arising in the renal parenchyma. Each histologic subtype is clinically and genetically unique. It is our understanding of the genetic basis for these cancers that has led to the variety of targeted systemic therapies now available in RCC. This review will cover the basic tumor biology behind each histology, as well as the associated therapeutic targets identified thus far. Mechanisms and associated side effects of the currently available drugs will be examined. Completed clinical trials will be discussed, leading into the rationale behind currently active trials, and future directions for drug development.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy

